Companies ›Healthcare ›IMVT.O

IMVT.O — NASDAQ Biotechnology & Medical Research

Imvt.O

$39,00

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

7,9B USD

P/E

—

EV / Rev

—

Div yield

—

Op margin

—

ROE

-58,5 %

Net margin

—

Debt / equity

0,00

Beta

—

52w range

—

Volume

Day range

—

Prev close

$33,41

Open

—

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

IMVT.O is a biotechnology company focused on healthcare diagnostics, developing and commercializing innovative diagnostic solutions for infectious diseases and other medical conditions.

Business. IMVT.O is a biotechnology and medical research company operating within the healthcare diagnostics industry. The firm generates revenue through a product-sale model, focusing on pharmaceuticals and medical research activities. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data. Consequently, the company is described at the industry level without geographic or segment-specific breakdowns.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryBiotechnology & Medical Research

ActivityHealthcare Diagnostics

Generated · model-assisted

Sell-side consensus

BUY18 analysts

13 buy5 hold0 sell

Avg 12m price target40,40

Analyst recommendations

18 analysts · consensus Buy

Buy13

Hold5

Sell0

12-month price target

40,40

Consensus of sell-side coverage.

Upcoming events

EarningsQ2 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

18 analysts · indicative

Ownership→

T. Rowe Price Investment Management, Inc.

largest disclosed fund holder

Profitability→

-58,5 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning IMVT.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to IMVT.O. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ2 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

IMVT.O is a biotechnology and medical research company operating within the healthcare diagnostics industry. The firm generates revenue through a product-sale model, focusing on pharmaceuticals and medical research activities. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data. Consequently, the company is described at the industry level without geographic or segment-specific breakdowns.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryBiotechnology & Medical Research

ActivityHealthcare Diagnostics

AI synthesis

GENERATED

IMVT.O has a market capitalization of $5.84 billion and a price-to-book ratio of 8.25, indicating a premium valuation relative to its book value. The company has no long-term debt and a debt-to-equity ratio of 0.0, suggesting a conservative capital structure. However, its liquidity position is rated as low, and it has a current ratio of 11.16, which is high but may not fully offset its negative operating and free cash flows of -$375.87 million and -$414.22 million, respectively.

Profitability metrics for IMVT.O are negative, with a return on equity of -58.5% and a return on assets of -53.31%. These figures are significantly below the industry norms for biotechnology firms, which typically aim for positive returns. The company reported a net loss of $413.84 million and an operating loss of $438.15 million, indicating ongoing financial challenges.

IMVT.O's revenue concentration is not disclosed in the available data, but the company operates in a single business segment focused on healthcare diagnostics. The geographic exposure is not specified, but the company is likely concentrated in the United States, given the lack of international revenue breakdown.

The company's growth trajectory is uncertain, with no specific revenue growth projections provided. Analysts have a mixed outlook, with a mean price target of $40.40 and a median of $42.00, suggesting potential upside from the current market price of $28.67. However, the company's negative cash flows and losses raise concerns about its ability to sustain operations and grow without external financing.

Risk factors for IMVT.O include its high valuation relative to book value, negative profitability, and lack of liquidity. The company has no immediate filing-based liquidity or dilution flags, but its negative cash flows and losses could necessitate future financing, which may involve equity dilution. The risk assessment indicates a low probability of dilution in the near term, but the potential for dilution remains a concern.

Recent events for IMVT.O include the publication of its latest financial data, which shows continued losses and negative cash flows. The company has not disclosed any major new product launches or strategic partnerships in the available data. Analysts have provided a range of price targets, with a strong-buy recommendation from seven analysts, indicating some optimism about the company's future.

Key takeaways

IMVT.O is a biotechnology company with a focus on healthcare diagnostics, operating in a high-growth but competitive industry.
The company has a high price-to-book ratio of 8.25, indicating a premium valuation relative to its book value.
IMVT.O is experiencing significant financial challenges, with a net loss of $413.84 million and an operating loss of $438.15 million.
Analysts have a mixed outlook, with a mean price target of $40.40 and a median of $42.00, suggesting potential upside from the current market price of $28.67.
The company has no long-term debt and a debt-to-equity ratio of 0.0, indicating a conservative capital structure.
IMVT.O's liquidity position is rated as low, and it has a current ratio of 11.16, which is high but may not fully offset its negative operating and free cash flows.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$39,00

Market cap

$5.84B

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

8.2x

P / Tangible bookⓘ

8.2x

Tangible book

$707.4M

Net cashⓘ

—

Current ratioⓘ

11.2

Debt / equityⓘ

0.0

ROAⓘ

-53.3%

ROEⓘ

-58.5%

Cash conversionⓘ

91.0%

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

Business relationships1 disclosed relationship · 1 type · extracted from filings & disclosures

Partners1

Hanall Biopharma Co Ltd009420.KSPartner95%Source ↗

Supply chain

Vendors → IMVT ↔ Partners → Customers · click any node to drill

1 mention in 10-K0 from corporate websites0 from news dispatches

Updated 2026-06-24

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

-2,62

Predicted surprise

-0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-05-06 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	-2,62
Revenue	—no estimate	—no estimate	0 USD
Operating income	—no estimate	—no estimate	-495,5M USD

Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution18 analysts

Strong buy7

Buy6

Hold5

Sell0

Strong sell0

12-month price target$40,40 · Median $42,00

Low $22,00High $66,00

Operating income · consensus-495,5M USD

EPS surprise

−4,2 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$22,00

Mean$40,40

Median$42,00

High$66,00

Spot$39,00

+3.6 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskLow

Filing-based flags

No immediate filing-based liquidity or dilution flags were detected.

Benchmarks vs cohort

ROE-58,5 %Bottom quartile

D/E0,00Above median

Cash Conv0,91Above median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net acquired 258 558 sh7 exercises · 11 grants11 insiders

Pande AtulDirector · Stock Option (right to buy) → Common StockDisposed 1 500 @ $8,43exercise · 2026-06-15
Fromkin Andrew J.Director · Stock Option (right to buy) → Common StockDisposed 31 668 @ $4,99exercise · 2026-05-28
Fromkin Andrew J.Director · Stock Option (right to buy) → Common StockDisposed 71 492 @ $7,94exercise · 2026-05-28
Fromkin Andrew J.Director · Stock Option (right to buy) → Common StockDisposed 77 181 @ $8,43exercise · 2026-05-28
Fromkin Andrew J.Director · Stock Option (right to buy) → Common StockDisposed 16 260 @ $14,70exercise · 2026-05-28
Pande AtulDirector · Stock Option (right to buy) → Common StockDisposed 6 000 @ $8,43exercise · 2026-05-20
Gloria MelanieChief Operating Officer · Stock Option (right to buy) → Common StockAcquired 121 063 @ $24,61grant · 2026-04-07
Girao TiagoChief Financial Officer · Stock Option (right to buy) → Common StockAcquired 94 002 @ $24,61grant · 2026-04-07
Bauer JakeDirector · Stock Option (right to buy) → Common StockAcquired 7 061 @ $24,61grant · 2026-04-07
Susman Robert GrahamDirector · Stock Option (right to buy) → Common StockAcquired 7 061 @ $24,61grant · 2026-04-07
Stout Jay SChief Technology Officer · Stock Option (right to buy) → Common StockAcquired 96 851 @ $24,61grant · 2026-04-07
Venker EricDirector, Chief Executive Officer · Stock Option (right to buy) → Common StockAcquired 336 043 @ $24,61grant · 2026-04-07
Van Tuyl ChristopherChief Legal Officer · Stock Option (right to buy) → Common StockAcquired 59 820 @ $24,61grant · 2026-04-07
Torti FrankDirector · Stock Option (right to buy) → Common StockAcquired 88 325 @ $24,61grant · 2026-04-07
Fromkin Andrew J.Director · Stock Option (right to buy) → Common StockAcquired 7 061 @ $24,61grant · 2026-04-07
Hughes Douglas J.Director · Stock Option (right to buy) → Common StockAcquired 7 061 @ $24,61grant · 2026-04-07
Pande AtulDirector · Stock Option (right to buy) → Common StockAcquired 7 061 @ $24,61grant · 2026-04-07
Venker EricDirector, Chief Executive Officer · Capped Value Appreciation Rights → Common StockDisposed 368 750 @ $14,46exercise · 2026-04-01

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)
Market Cap
market_price * shares_outstanding_diluted
Return On Equity
net_income / total_equity
Price To Tangible Book
market_price / (tangible_book_value / shares_outstanding_diluted)
Debt To Equity
(short_term_debt + long_term_debt) / total_equity

Source documents

IMVT.O Market data — financials · 2026-05-28
Immunovant Inc Market data — analyst estimates · 2026-05-28

Ownership & reference

Top holders

T. Rowe Price Investment Management, Inc.Investment Managers · as of 2026-03-310,06 %$0M
Jennison Associates LLCInvestment Managers · as of 2026-03-310,05 %$79M
FMR LLCInstitutional Investor · as of 2026-03-310,02 %$421M
Nuveen LLCInvestment Managers · as of 2024-12-310,01 %$23M
Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,01 %$44M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,01 %$96M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$113M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$52M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$17M
BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$130M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$198M
Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$16M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$17M
Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$5M
T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$2M
JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,00 %$1M
Invesco QQQ TrustFunds · as of 2026-03-310,00 %$2M
Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$1M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$1M
Victory Capital Management Inc.Investment Managers · as of 2026-03-310,00 %$0M
Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,00 %$1M
Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$0M
PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M
JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M

Insider activity

Net selling0 buys · 21 sellsnet -$9,9M11 insiders · last 365d

Van Tuyl ChristopherChief Legal Officer · Common StockSold 2 634 @ $35,39$93K · 2026-06-18
Pande AtulDirector · Common StockOther 1 500 @ $8,43$13K · 2026-06-15
Pande AtulDirector · Common StockSold 1 500 @ $34,02$51K · 2026-06-15
Fromkin Andrew J.Director · Common StockOther 31 668 @ $4,99$158K · 2026-05-28
Fromkin Andrew J.Director · Common StockOther 71 492 @ $7,94$568K · 2026-05-28
Fromkin Andrew J.Director · Common StockOther 77 181 @ $8,43$651K · 2026-05-28
Fromkin Andrew J.Director · Common StockOther 16 260 @ $14,70$239K · 2026-05-28
Fromkin Andrew J.Director · Common StockSold 11 483 @ $32,64$375K · 2026-05-28
Fromkin Andrew J.Director · Common StockSold 210 468 @ $33,56$7,1M · 2026-05-28
Gloria MelanieChief Operating Officer · Common StockSold 249 @ $30,41$8K · 2026-05-20
Gloria MelanieChief Operating Officer · Common StockSold 1 168 @ $32,15$38K · 2026-05-20
Gloria MelanieChief Operating Officer · Common StockSold 1 698 @ $32,95$56K · 2026-05-20
Pande AtulDirector · Common StockOther 6 000 @ $8,43$51K · 2026-05-20
Pande AtulDirector · Common StockSold 6 000 @ $32,00$192K · 2026-05-20
Susman Robert GrahamDirector · Common StockSold 2 502 @ $27,17$68K · 2026-05-01
Girao TiagoChief Financial Officer · Common StockSold 25 760 @ $29,62$763K · 2026-04-23
Stout Jay SChief Technology Officer · Common StockSold 2 754 @ $29,62$82K · 2026-04-23
Van Tuyl ChristopherChief Legal Officer · Common StockSold 5 165 @ $24,83$128K · 2026-04-08
Gloria MelanieChief Operating Officer · Common StockSold 8 722 @ $24,83$217K · 2026-04-08
Stout Jay SChief Technology Officer · Common StockSold 8 614 @ $24,83$214K · 2026-04-08
Stout Jay SChief Technology Officer · Common StockSold 1 518 @ $24,83$38K · 2026-04-08
Fromkin Andrew J.Director · Common StockOther 13 880 · 2026-04-07
Torti FrankDirector · Common StockOther 174 189 · 2026-04-07
Hughes Douglas J.Director · Common StockOther 13 880 · 2026-04-07
Pande AtulDirector · Common StockOther 13 880 · 2026-04-07

Short positioning

17.8Mshares short-1.3% vs prior

16.72days to cover

68.0%short of daily vol

145fails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

IMVT.OCanonical

NASDAQ · USD

Intel & risk

PredictorBeat prob45 %Surprise-0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskLow

No immediate filing-based liquidity or dilution flags were detected.

Relationship graph

This companySectorPartners

Evidence & claims

From filings & derived data

EPS (basic) (YoY) (2026-03-31 vs 2025-03-31): -1.5%Derived (calculated)
Operating cash flow (YoY) (2026-03-31 vs 2025-03-31): -8.4%Derived (calculated)
Net income (YoY) (2026-03-31 vs 2025-03-31): -22.2%Derived (calculated)
EPS (diluted) (YoY) (2026-03-31 vs 2025-03-31): -1.5%Derived (calculated)
Capex (YoY) (2026-03-31 vs 2025-03-31): -98.9%Derived (calculated)
Operating cash flow (annual): USD -407.31MSEC XBRL filing
EPS (diluted) (annual): USD-PER-SHARES -3SEC XBRL filing
Total operating expenses (annual): USD 532.9MSEC XBRL filing
Pre-tax income (annual): USD -505.39MSEC XBRL filing
EPS (basic) (annual): USD-PER-SHARES -3SEC XBRL filing
Net income (annual): USD -505.61MSEC XBRL filing
Capex (annual): USD 8KSEC XBRL filing
Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -3.0%Derived (calculated)
Current ratio (FY 2025-12-31): 15.74xDerived (calculated)
Debt-to-equity (FY 2025-12-31): 0.07xDerived (calculated)
Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 165.4%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 179.7%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): 150.0%Derived (calculated)
Total assets (annual): USD 1.05BSEC XBRL filing
Current assets (annual): USD 1.04BSEC XBRL filing
Cash & equivalents (annual): USD 994.52MSEC XBRL filing
Shareholders' equity (annual): USD 986.13MSEC XBRL filing
Current liabilities (annual): USD 66.26MSEC XBRL filing
Total liabilities (annual): USD 66.26MSEC XBRL filing

Showing 24 of 39 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ2 2026 earnings (expected) estimated date

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-06-18 00:00 UTCINSIDER4 insider transactions — 2026-06 · net sell $132k 1 derivative

2026-06-18INSIDERVan Tuyl Christopher sold 2.6k sh — Chief Legal Officer ~$93k

2026-06-15INSIDERPande Atul transacted 1.5k sh — Director ~$13k

2026-06-15INSIDERPande Atul sold 1.5k sh — Director ~$51k

2026-06-15INSIDERPande Atul disposed of 1.5k sh Stock Option (right to buy) — Director

2026-05-28 00:00 UTCINSIDER17 insider transactions — 2026-05 · net sell $6.1M 5 derivative

2026-05-28INSIDERFromkin Andrew J. transacted 31.7k sh — Director ~$158k

2026-05-28INSIDERFromkin Andrew J. transacted 71.5k sh — Director ~$568k

2026-05-28INSIDERFromkin Andrew J. transacted 77.2k sh — Director ~$651k

2026-05-28INSIDERFromkin Andrew J. transacted 16.3k sh — Director ~$239k

2026-05-28INSIDERFromkin Andrew J. sold 11.5k sh — Director ~$375k

2026-05-28INSIDERFromkin Andrew J. sold 210.5k sh — Director ~$7.06M

2026-05-28INSIDERFromkin Andrew J. disposed of 31.7k sh Stock Option (right to buy) — Director

2026-05-28INSIDERFromkin Andrew J. disposed of 16.3k sh Stock Option (right to buy) — Director

2026-05-28INSIDERFromkin Andrew J. disposed of 77.2k sh Stock Option (right to buy) — Director

2026-05-28INSIDERFromkin Andrew J. disposed of 71.5k sh Stock Option (right to buy) — Director

2026-05-20FILING10-K filing →

2026-05-20FILING8-K filing →

2026-05-20INSIDERGloria Melanie sold 249 sh — Chief Operating Officer ~$8k

2026-05-20INSIDERGloria Melanie sold 1.2k sh — Chief Operating Officer ~$38k

2026-05-20INSIDERGloria Melanie sold 1.7k sh — Chief Operating Officer ~$56k

2026-05-20INSIDERPande Atul transacted 6.0k sh — Director ~$51k

2026-05-20INSIDERPande Atul sold 6.0k sh — Director ~$192k

2026-05-20INSIDERPande Atul disposed of 6.0k sh Stock Option (right to buy) — Director

2026-05-01INSIDERSusman Robert Graham sold 2.5k sh — Director ~$68k

2026-04-23 00:00 UTCINSIDER33 insider transactions — 2026-04 · net sell $4.9M 12 derivative

2026-04-23INSIDERGirao Tiago sold 25.8k sh — Chief Financial Officer ~$763k

2026-04-23INSIDERStout Jay S sold 2.8k sh — Chief Technology Officer ~$82k

2026-04-08INSIDERVan Tuyl Christopher sold 5.2k sh — Chief Legal Officer ~$128k

2026-04-08INSIDERGloria Melanie sold 8.7k sh — Chief Operating Officer ~$217k

2026-04-08INSIDERStout Jay S sold 8.6k sh — Chief Technology Officer ~$214k

2026-04-08INSIDERStout Jay S sold 1.5k sh — Chief Technology Officer ~$38k

2026-04-07INSIDERFromkin Andrew J. transacted 13.9k sh — Director

2026-04-07INSIDERTorti Frank transacted 174.2k sh — Director

2026-04-07INSIDERHughes Douglas J. transacted 13.9k sh — Director

2026-04-07INSIDERPande Atul transacted 13.9k sh — Director

2026-04-07INSIDERGirao Tiago acquired 94.0k sh Stock Option (right to buy) — Chief Financial Officer

2026-04-07INSIDERVenker Eric acquired 336.0k sh Stock Option (right to buy) — Director, Chief Executive Officer

Showing the 40 most recent of 59 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread